Eun Yang
Stock Analyst at Jefferies
(0.51)
# 3,948
Out of 4,876 analysts
43
Total ratings
32%
Success rate
-25.82%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $284.27 | +51.97% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $2.38 | +236.13% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $5.57 | +384.74% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.34 | +336.05% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $44.86 | -26.44% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.81 | +1,446.96% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $20.68 | +30.56% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.73 | +304.62% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.38 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $2.42 | +933.06% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $0.09 | +87,210.83% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $128.11 | -34.43% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.10 | +2,172.73% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $11.30 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $13.20 | +165.15% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $277.13 | -20.61% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $29.64 | +4.59% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $126.08 | +145.88% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $110.67 | -27.71% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $284.27
Upside: +51.97%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $2.38
Upside: +236.13%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $5.57
Upside: +384.74%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.34
Upside: +336.05%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $44.86
Upside: -26.44%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.81
Upside: +1,446.96%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $20.68
Upside: +30.56%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.73
Upside: +304.62%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.38
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $2.42
Upside: +933.06%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $0.09
Upside: +87,210.83%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $128.11
Upside: -34.43%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.10
Upside: +2,172.73%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $11.30
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $13.20
Upside: +165.15%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $277.13
Upside: -20.61%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $29.64
Upside: +4.59%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $126.08
Upside: +145.88%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $110.67
Upside: -27.71%